Pfizer -- December 13, 2022

Disclaimer: this is not an investment site.  Do not make any investment, financial, job, career, travel, or relationship decisions based on what you read here or think you may have read here.

All my posts are done quickly: there will be content and typographical errors. If anything on any of my posts is important to you, go to the source. If/when I find typographical / content errors, I will correct them.     

Updates

December 21, 2022: a most interesting story.

December 13, 2022:

• Moderna-Merck-partnered cancer vaccine meets primary efficacy endpoint.
• link here: for treatment of stage III/IV melanoma, following complete resection.
  

December 13, 2022:

• Pfizer sees $10 billion - $15 billion in potential revenue from mRNA vaccines by 2030.

Original Post

After posting this note below, yesterday, I received a note from a reader regarding Pfizer's history from 2012 - 2016 time frame. Amazing how fast things can change.   

Best managed, one of five metrics -- financial strength:

Before getting to Pfizer, look at Moderna today: up 24%:

From today:

From yesterday:

Link here.

“Managers,” Peter Drucker wrote, “must understand that business results depend on a balance of efforts and results in a number of areas."

Yet if the Drucker Institute’s measure of corporate effectiveness is any indication, that is much easier said than done.

Of the 902 companies that we analyzed this year, a mere seven of them scored 60 or higher, on our 0-100 scale, in every category of performance that we examined: customer satisfaction, employee engagement and development, innovation, social responsibility and financial strength. 

The seven companies:

• Accenture PLC
• Apple Inc.
• HP Inc.
• Mastercard Inc.
• Pfizer Inc.
• Procter & Gamble Co.
• Visa Inc.